MX376058B - Uso de peptidos glp-1 de accion prolongada. - Google Patents

Uso de peptidos glp-1 de accion prolongada.

Info

Publication number
MX376058B
MX376058B MX2019008148A MX2019008148A MX376058B MX 376058 B MX376058 B MX 376058B MX 2019008148 A MX2019008148 A MX 2019008148A MX 2019008148 A MX2019008148 A MX 2019008148A MX 376058 B MX376058 B MX 376058B
Authority
MX
Mexico
Prior art keywords
peptides
long
acting glp
glp
acting
Prior art date
Application number
MX2019008148A
Other languages
English (en)
Spanish (es)
Other versions
MX2019008148A (es
Inventor
Christine Bjørn Jensen
Mads Frederik Rasmussen
Milan Zdravkovic
Peter Kristensen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2019008148A publication Critical patent/MX2019008148A/es
Publication of MX376058B publication Critical patent/MX376058B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2019008148A 2012-07-01 2013-06-21 Uso de peptidos glp-1 de accion prolongada. MX376058B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12174535 2012-07-01
US201261694837P 2012-08-30 2012-08-30
US201261708162P 2012-10-01 2012-10-01
EP12186781 2012-10-01
PCT/EP2013/063004 WO2014005858A1 (en) 2012-07-01 2013-06-21 Use of long-acting glp-1 peptides

Publications (2)

Publication Number Publication Date
MX2019008148A MX2019008148A (es) 2019-09-05
MX376058B true MX376058B (es) 2025-03-07

Family

ID=65858459

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2019008148A MX376058B (es) 2012-07-01 2013-06-21 Uso de peptidos glp-1 de accion prolongada.
MX2014014946A MX366405B (es) 2012-07-01 2013-06-21 Uso de peptidos glp-1 de accion prolongada.
MX2020010693A MX2020010693A (es) 2012-07-01 2014-12-05 Uso de peptidos glp-1 de accion prolongada.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2014014946A MX366405B (es) 2012-07-01 2013-06-21 Uso de peptidos glp-1 de accion prolongada.
MX2020010693A MX2020010693A (es) 2012-07-01 2014-12-05 Uso de peptidos glp-1 de accion prolongada.

Country Status (17)

Country Link
US (2) US9764003B2 (cg-RX-API-DMAC7.html)
EP (3) EP3689365B1 (cg-RX-API-DMAC7.html)
JP (1) JP6059802B2 (cg-RX-API-DMAC7.html)
AU (3) AU2013286177B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014032938A2 (cg-RX-API-DMAC7.html)
CA (1) CA2877056A1 (cg-RX-API-DMAC7.html)
DK (1) DK2866825T3 (cg-RX-API-DMAC7.html)
ES (2) ES2796839T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20200889T1 (cg-RX-API-DMAC7.html)
HU (2) HUE072859T2 (cg-RX-API-DMAC7.html)
MX (3) MX376058B (cg-RX-API-DMAC7.html)
PL (2) PL2866825T3 (cg-RX-API-DMAC7.html)
PT (1) PT2866825T (cg-RX-API-DMAC7.html)
RS (2) RS60432B1 (cg-RX-API-DMAC7.html)
RU (2) RU2018117557A (cg-RX-API-DMAC7.html)
SI (1) SI2866825T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014005858A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2651398T (pt) 2010-12-16 2018-03-09 Novo Nordisk As Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
MY161450A (en) 2011-04-12 2017-04-14 Novo Nordisk As Double-acylated glp-1 derivatives
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
CN104487056A (zh) 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
JP6059802B2 (ja) 2012-07-01 2017-01-11 ノヴォ ノルディスク アー／エス 長時間作用型ｇｌｐ−１ペプチドの使用
PL2991671T3 (pl) 2013-05-02 2019-01-31 Novo Nordisk As Doustne dawkowanie związków glp-1
KR102127624B1 (ko) * 2014-10-16 2020-06-29 얀마 파워 테크놀로지 가부시키가이샤 작업 차량
GB201621987D0 (en) * 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
DE102017106216A1 (de) * 2017-03-22 2018-09-27 Amw Gmbh Extrudierte Depotform zur anhaltenden Wirkstofffreisetzung
TWI847306B (zh) 2017-08-24 2024-07-01 丹麥商諾佛 儂迪克股份有限公司 Ｇｌｐ-１組成物及其用途
BR112020006246A2 (pt) * 2017-10-12 2021-03-30 Novo Nordisk A/S Método para controle do peso de um sujeito em necessidade
GB201720187D0 (en) * 2017-12-04 2018-01-17 Imperial Innovations Ltd Novel Compounds
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
US20210162013A1 (en) * 2018-08-03 2021-06-03 Brown University Compositions and methods for improving the bioavailability of glp1 and analogues thereof
WO2020176678A1 (en) * 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for glp1 receptor
AU2020377469A1 (en) * 2019-11-06 2022-04-28 Novo Nordisk A/S GLP-1 receptor agonists in dementia
MX2022008139A (es) * 2019-12-30 2022-10-03 Gan & Lee Pharmaceuticals Co Ltd Compuestos de glp-1 de acción prolongada.
PE20230819A1 (es) * 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
CN112768087A (zh) * 2020-12-23 2021-05-07 吉林大学 利用孟德尔随机化方法验证索马鲁肽口服制剂预防二型糖尿病的用途
EP4359074A4 (en) * 2021-06-24 2025-06-04 Gila Therapeutics, Inc. METHODS AND KITS FOR INDUCTING SATOURAGE AND TREATMENT OF METABOLIC DISEASES
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
MX2024003872A (es) 2021-09-27 2024-04-19 Terns Pharmaceuticals Inc Acidos carboxilicos de benzimidazol como agonistas de glp-1r.
AU2022375634A1 (en) 2021-10-25 2024-06-06 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
WO2023086499A1 (en) 2021-11-10 2023-05-19 I2O Therapeutics, Inc. Ionic liquid compositions
CN114621339B (zh) * 2021-12-28 2022-09-23 北京惠之衡生物科技有限公司 一种长效glp-1衍生物
IL315151A (en) 2022-02-23 2024-10-01 Terns Pharmaceuticals Inc Compounds as glp-1r agonists
WO2023225370A1 (en) * 2022-05-19 2023-11-23 Vault Bioventures, Inc. Obesity treatment and prevention methods
EP4642440A1 (en) 2022-12-30 2025-11-05 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration
KR20250166323A (ko) 2023-04-07 2025-11-27 테른스 파마슈티칼스, 인크. 간 장애 또는 심장대사 질환의 치료에 사용하기 위한 thr베타 효현제 및 glp-1r 효현제를 포함하는 조합
WO2025024455A1 (en) 2023-07-24 2025-01-30 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for delivery of therapeutic peptides
WO2025165146A1 (ko) * 2024-01-29 2025-08-07 주식회사 티온랩테라퓨틱스 세마글루타이드 또는 티르제파타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용으로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법
CN118845644B (zh) * 2024-09-27 2025-01-17 杭州信海医药科技有限公司 一种司美格鲁肽注射液的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
DE69737479T4 (de) 1996-08-30 2010-05-06 Novo Nordisk A/S Glp-1 derivate
DE60224284T2 (de) * 2001-06-28 2008-12-18 Novo Nordisk A/S Stabile formulierung von modifiziertem glp-1
JP4949838B2 (ja) 2003-09-19 2012-06-13 ノヴォ ノルディスク アー／エス 新規ｇｌｐ−１誘導体
CN1882356B (zh) 2003-11-20 2015-02-25 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
WO2006051110A2 (en) 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of insulinoptropic peptides
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
KR20150042304A (ko) 2006-04-14 2015-04-20 맨카인드 코포레이션 글루카곤 유사 펩타이드 1 （ｇｌｐ-1） 약제학적 제제
WO2008116088A1 (en) 2007-03-20 2008-09-25 Nippon Kayaku Kabushiki Kaisha Method to monitor drug efficacy in diabetic patients using an assay for 1,5-anhydro-d-glucitol
JP2011504871A (ja) 2007-06-01 2011-02-17 ノボ・ノルデイスク・エー／エス 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト
WO2009030738A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
CN101842386A (zh) 2007-09-05 2010-09-22 诺沃-诺迪斯克有限公司 截短的glp-1衍生物和它们的治疗用途
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
ES2620610T3 (es) 2008-12-10 2017-06-29 Glaxosmithkline Llc Composiciones farmacéuticas de albiglutide
CN117547538A (zh) 2009-02-13 2024-02-13 勃林格殷格翰国际有限公司 包含dpp-4抑制剂(利格列汀)任选地组合其它抗糖尿病药的抗糖尿病药物
CN102791731B (zh) 2009-12-16 2016-04-20 诺沃—诺迪斯克有限公司 Glp-1类似物和衍生物
CN107961377B (zh) * 2010-05-05 2022-11-22 勃林格殷格翰国际有限公司 组合疗法
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
PT2651398T (pt) 2010-12-16 2018-03-09 Novo Nordisk As Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
CN102229668A (zh) 2011-06-03 2011-11-02 浙江贝达药业有限公司 一种glp-1衍生物及其应用
US20140220134A1 (en) 2011-06-24 2014-08-07 Astrazeneca Pharamceuticals LP Method for treating diabetes with extended release formulation of glp-1 receptor agonists
JP6059802B2 (ja) 2012-07-01 2017-01-11 ノヴォ ノルディスク アー／エス 長時間作用型ｇｌｐ−１ペプチドの使用

Also Published As

Publication number Publication date
US9764003B2 (en) 2017-09-19
PL3689365T3 (pl) 2025-11-12
DK2866825T3 (da) 2020-06-08
JP2015522573A (ja) 2015-08-06
EP4406593A3 (en) 2024-10-23
HRP20200889T1 (hr) 2020-09-04
US20150190474A1 (en) 2015-07-09
ES2796839T3 (es) 2020-11-30
US10335462B2 (en) 2019-07-02
RU2657573C2 (ru) 2018-06-14
EP3689365A1 (en) 2020-08-05
EP3689365B1 (en) 2025-08-06
MX366405B (es) 2019-07-08
RS67258B1 (sr) 2025-10-31
CA2877056A1 (en) 2014-01-09
WO2014005858A1 (en) 2014-01-09
HRP20251088T1 (hr) 2025-11-07
ES3041720T3 (en) 2025-11-14
US20180085435A1 (en) 2018-03-29
HUE072859T2 (hu) 2025-12-28
AU2018202504B2 (en) 2020-05-07
AU2020202573A1 (en) 2020-05-07
AU2018202504A1 (en) 2018-05-10
PL2866825T3 (pl) 2021-02-22
RU2018117557A3 (cg-RX-API-DMAC7.html) 2021-08-20
AU2013286177B2 (en) 2018-04-26
MX2019008148A (es) 2019-09-05
RU2015101826A (ru) 2016-08-20
EP3689365C0 (en) 2025-08-06
JP6059802B2 (ja) 2017-01-11
BR112014032938A2 (pt) 2017-08-01
EP4406593A2 (en) 2024-07-31
RS60432B1 (sr) 2020-07-31
EP2866825B1 (en) 2020-04-08
SI2866825T1 (sl) 2020-07-31
AU2013286177A1 (en) 2015-01-15
HUE049152T2 (hu) 2020-09-28
PT2866825T (pt) 2020-07-15
AU2020202573B2 (en) 2023-04-20
RU2018117557A (ru) 2019-03-22
MX2014014946A (es) 2015-04-08
MX2020010693A (es) 2020-11-06
EP2866825A1 (en) 2015-05-06

Similar Documents

Publication Publication Date Title
MX376058B (es) Uso de peptidos glp-1 de accion prolongada.
CY1121497T1 (el) Συριγγα
CY1120730T1 (el) Απο του στοματος χορηγουμενη δοσολογια ενωσεων glp-1
EA201490070A1 (ru) Коантагонисты глюкагонового рецептора/glp-1-рецептора
EA201590058A1 (ru) Аналоги глюкагона
CL2015000942A1 (es) Compuestos de benceno sustituido.
MX2013015168A (es) Co-agonista del receptor de glucagon/glp-1.
MX2016007063A (es) Peptidos terapeuticos.
EA201490644A1 (ru) Терапевтические пептиды
EA201391764A1 (ru) Агонисты рецептора glp-1/глюкагона длительного действия
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
EA201690613A1 (ru) Улучшенные составы на основе аденовирусов
EA201401204A1 (ru) Антитела к il-23p19
MX381278B (es) Composición para la estimulación ovárica controlada.
MX370264B (es) Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
EA201590359A1 (ru) Лечение ревматоидного артрита
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
TR201100150A2 (tr) Suda çözünür dozaj formları
PH12017500923A1 (en) New dosage and use of a a2a antagonist
MX377995B (es) Moléculas de unión al receptor bag3 para uso como un medicamento.
CY1117740T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης
ES2426017A2 (es) Microemulsión que comprende colagenasa y usos
TN2013000524A1 (en) Glucagon/glp-1 receptor co-agonists

Legal Events

Date Code Title Description
FG Grant or registration
GD Licence granted